We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $65.15, moving +1.57% from the previous trading session. This change outpaced the S&P 500's 0.47% gain on the day. Elsewhere, the Dow gained 0.31%, while the tech-heavy Nasdaq added 0.34%.
Prior to today's trading, shares of the HIV and hepatitis C drugmaker had gained 0.71% over the past month. This has outpaced the Medical sector's loss of 4.29% and lagged the S&P 500's gain of 4.67% in that time.
Investors will be hoping for strength from GILD as it approaches its next earnings release, which is expected to be May 2, 2019. On that day, GILD is projected to report earnings of $1.62 per share, which would represent year-over-year growth of 9.46%. Meanwhile, our latest consensus estimate is calling for revenue of $5.34 billion, up 4.92% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $6.65 per share and revenue of $22.04 billion. These totals would mark changes of -0.3% and -0.4%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for GILD. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.04% higher. GILD currently has a Zacks Rank of #2 (Buy).
In terms of valuation, GILD is currently trading at a Forward P/E ratio of 9.65. Its industry sports an average Forward P/E of 21.02, so we one might conclude that GILD is trading at a discount comparatively.
Also, we should mention that GILD has a PEG ratio of 0.95. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.84 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 64, which puts it in the top 26% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow GILD in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $65.15, moving +1.57% from the previous trading session. This change outpaced the S&P 500's 0.47% gain on the day. Elsewhere, the Dow gained 0.31%, while the tech-heavy Nasdaq added 0.34%.
Prior to today's trading, shares of the HIV and hepatitis C drugmaker had gained 0.71% over the past month. This has outpaced the Medical sector's loss of 4.29% and lagged the S&P 500's gain of 4.67% in that time.
Investors will be hoping for strength from GILD as it approaches its next earnings release, which is expected to be May 2, 2019. On that day, GILD is projected to report earnings of $1.62 per share, which would represent year-over-year growth of 9.46%. Meanwhile, our latest consensus estimate is calling for revenue of $5.34 billion, up 4.92% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $6.65 per share and revenue of $22.04 billion. These totals would mark changes of -0.3% and -0.4%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for GILD. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.04% higher. GILD currently has a Zacks Rank of #2 (Buy).
In terms of valuation, GILD is currently trading at a Forward P/E ratio of 9.65. Its industry sports an average Forward P/E of 21.02, so we one might conclude that GILD is trading at a discount comparatively.
Also, we should mention that GILD has a PEG ratio of 0.95. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.84 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 64, which puts it in the top 26% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow GILD in the coming trading sessions, be sure to utilize Zacks.com.